FindTrial
Sign In

SPN-810

DRUG5 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

Attention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity Disorder (ADHD)Conduct DisorderImpulsive AggressionImpulsive Aggression Comorbid With ADHD

Phase 2

Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
CompletedNCT00626236
Supernus Pharmaceuticals, Inc.Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Start: 2008-10-21End: 2009-09-23Updated: 2025-12-09
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
CompletedNCT01364662
Supernus Pharmaceuticals, Inc.Impulsive Aggression Comorbid With ADHD
Start: 2011-06-30End: 2012-10-31Updated: 2021-02-11
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
TerminatedNCT03638466
Supernus Pharmaceuticals, Inc.Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Start: 2019-05-30End: 2019-11-07Updated: 2025-05-02

Phase 3

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
TerminatedNCT02691182
Supernus Pharmaceuticals, Inc.Attention Deficit Hyperactivity Disorder (ADHD)
Start: 2016-04-30End: 2021-05-31Updated: 2024-05-16
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
TerminatedNCT03597503
Supernus Pharmaceuticals, Inc.Attention Deficit Hyperactivity Disorder
Start: 2018-07-31End: 2020-01-22Updated: 2024-04-24